UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit
£240m Investment Committed
Executive Summary
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
You may also be interested in...
More Candidate COVID-19 Vaccines Expected To Enter WHO’s Global Trial
A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.
UK Vaccines Business Pushes Wockhardt To Sales Growth
Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.
Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.